DEXLANSOPRAZOLE

SynDRA canonical compound SYN0023627 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	ATP4A \| CYP2C19
Mechanism of action	ATPase inhibitor
Indication	erosive esophagitis (EE) \| gastroesophageal reflux disease (GERD)
Disease area	gastroenterology

All known targets

dexlansoprazole sesquihydrate
R-Lansoprazole
(R)-Lansoprazole
kapidex
dexilant
TAK-390
TAK-390MR
Dexlansoprazol
Lansoprazole r-form
(r)-lansoprazole
Kapidex
Lansoprazole, (r)-
NSC-758710
T-168390
Dexilant
Dexilant solutab
R-(+)-LANSOPRAZOLE
Dexilant Solutab
UNII-UYE4T5I70X
(r)-(+)-lansoprazole
UYE4T5I70X
AK170558
2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole
(R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
Dexlansoprazole (INN/USAN)
KS-1075
Lansoprazole
TAK 390
NSC 758710
Lansoprazole r-
R Lansoprazole
dexlansoprazol
dexlansoprazolum
Lansoprazole, R-
(+)-lansoprazole
R-Isomer Lansoprazole
RefChem:54964